Search

1 to 10 of 110
Sort by

Event
Immuno-Oncology Young Investigators' Forum

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in collaboration with the Society for Immunotherapy of Cancer. This program is ideally suited for North American-based junior faculty, fellows, and postdoctoral researchers (MDs, DOs,...

 04-16-2020 08:00 - 04-18-2020 20:00 CT
 Houston TX



Library Entry
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and maintains self-tolerance. This first-in-human study investigated the therapeutic use of...


Library Entry
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly...





Library Entry
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell dysfunction in cancer, it is now well-accepted that interruption of PD-1/PD-L1 axes...



Library Entry
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

Dysregulation in calcium (Ca 2+ ) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca 2+ pathway has been associated with disease progression, the importance of the newly described constitutive Ca 2+ entry (CE) pathway is less...